A Study of SIGX1094R in Patients With Advanced Solid Tumors

Summary

This is a phase I clinical, first-in-human study of SIGX1094R monotherapy. The goal of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), anti-tumor activity and food effect of SIGX1094R in patients with advanced solid tumors.

Timeline

Start

2024-12-12

Primary completion

2026-10

Completion

2026-12

Drugs

Indications